Attached files
file | filename |
---|---|
8-K - CDEX INC | m2111038k.htm |
EX-99.3 - CONSULTING AGREEMENT - CDEX INC | ex99_3.htm |
EX-99.2 - PRESS RELEASE, DATED FEBRUARY 11, 2010 - CDEX INC | ex99_2.htm |
EX-99.4 - CEO CORNER: WHAT'S NEW! - CDEX INC | ex99_4.htm |
EXHIBIT
99.1
CDEX
APPOINTS GREGORY FIRMBACH AS PRESIDENT
Tucson, Arizona – February 10, 2010
– CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com)
announced today that its Board of Directors has appointed Gregory Firmbach as
its new President. Firmbach, formerly CDEX Senior Vice President, has
served for over 25 years in senior positions in the healthcare
industry. He has led divisions and companies (both public and
private) in all aspects of successful development, launch and expansion of both
software and hardware products related to the healthcare industry. In
his new role, he will lead the company’s strategic growth.
“Greg is
a seasoned executive with outstanding credentials in the successful development
and launch of healthcare products in both public and private companies,” said
Malcolm Philips, CDEX CEO. “He has designed and implemented our sales
and marketing strategies during these turbulent economic times and his
appointment gives greater focus to revenue production as our continuing top
priority.”
“I am
honored with this appointment and will continue to make revenue production the
top priority for CDEX,” said Firmbach. “We are ideally positioned to make 2010 a
banner year focused on revenue growth and product development. We
recently enhanced our revenue model to ready our company for growth including
significant changes to our customer service and marketing focus.”
“The goal
I am setting for the Medication Safety Division is to establish the CDEX
ValiMed™ Medication Validation System (MVS) as the standard for prevention of
human error in the compounding of high risk medications and the diversion of
hospital narcotics,” Firmbach continued.
Firmbach
said the company will also fully support the efforts of the Emily Jerry
Foundation and The Quaid Foundation to prevent human error in hospitals. The
Emily Jerry Foundation recently endorsed the life-saving capability of the CDEX
technology. The ValiMed MVS delivers a real time validation of The
Right Drug at The Right Dose for about $2.50 per test.
About
CDEX
CDEX
develops, manufactures and globally distributes products to the healthcare and
security markets. The ValiMed product line provides life-saving
validation of high-risk medications and returned narcotics. The ID2™
product line detects trace amounts of illegal drugs, such as
methamphetamine. CDEX expects to advance its patented technologies to
serve additional markets. To meet its plans, CDEX must strengthen its financial
position as stated periodically in its SEC filings. For more
information, contact Malcolm Philips at mphilips@cdex-inc.com.
Non-historical
statements are forward-looking, as defined in federal securities laws, and
generally can be identified by words such as "expects," "plans," "may,"
"believes," "should," "intends," and similar words. These statements pose risks
that cannot be accurately predicted. Consequently, results may differ
materially from those expressed or implied. Such risks and uncertainties
include, without limitation, the effectiveness, profitability and marketability
of products, the protection of intellectual property and proprietary
information, and other risks detailed periodically in filings with the SEC.
There is no obligation to update any forward-looking statements.
4555 S.
Palo Verde Rd. Suite 123 Tucson, AZ
85714 (520) 745-5172
www.cdexinc.com